Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P, Foster B, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun L, Valdivieso M, Baker L. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clinical Cancer Research 1995, 1: 1487-93. PMID: 9815948.Peer-Reviewed Original ResearchMeSH KeywordsAcridinesAdultAgedAntineoplastic AgentsDrug Administration ScheduleFemaleHumansInfusions, IntravenousLeukopeniaMaleMiddle AgedNauseaNeoplasmsPyrazolesVomitingConceptsGrade IV toxicityStarting doseDose escalationClinical trialsPhase I clinical trialNext dose escalationAcceptable toxicity profilePhase II trialDose-limiting toxicityPeak plasma levelsPre-clinical efficacyMultidrug-resistant tumor cellsMurine solid tumorsII trialTreatment coursePlasma levelsGrade IInterpatient variationIntermediate dosePreclinical characteristicsToxicity profilePharmacokinetic parametersDose levelsSolid tumorsTotal dosePhase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks
Foster B, LoRusso P, Poplin E, Zalupski M, Valdivieso M, Wozniak A, Flaherty L, Kasunic D, Earhart R, Baker L. Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks. Investigational New Drugs 1995, 13: 321-326. PMID: 8824350, DOI: 10.1007/bf00873138.Peer-Reviewed Original ResearchConceptsMinute IV infusionTreatment scheduleM2/dayIV infusionPhase II starting doseRefractory soft tissue sarcomasConsecutive daysPhase IUnique alkylating agentRefractory solid tumorsPhase I trialSoft tissue sarcomasAdditional phase IPreclinical toxicology studiesBroad antitumor activityPotent synthetic analogsAnaphylactoid syndromeStarting doseI trialPartial responseAntitumor responseCumulative myelosuppressionTissue sarcomasTherapeutic dosesCytotoxic treatment